 |
 |
Safety concerns which have impeded the use of a drug effective against Parkinson's disease may not be justified, according to a study by a team at the Salpetriere Hospital in Paris, France, and collaborators at the Instituto de Investigaciones Farmacologicas in Argentina. They found that levodopa did not accelerate the death of already-fragile nerve cells in an animal model of the disease, as some physicians believe (Annals of Neurology, May 1998). However, the authors suggest that it might be beneficial to administer the lowest clinically-useful dose of L-dopa to PD patients, especially those in the early stages of the disease. <<Marketletter -- 05-11-98>> John Stafford -- http://pw2.netcom.com/~johnws/index.html -- [log in to unmask] ................... Si fallatis officium, quaestor infinitius eat se quicquam scire de factis vestris.